Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE).
Journal: Journal of the National Cancer Institute
Published: March 24, 2026
Stage acoustics for chamber music ensembles: Architectural and acoustic predictors.
Journal: The Journal of the Acoustical Society of America
Published: January 29, 2026
Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer.
Journal: Breast cancer research and treatment
Published: May 16, 2025
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 20, 2024
Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism.
Journal: JCO precision oncology
Published: July 11, 2024
Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression.
Journal: Breast cancer research and treatment
Published: May 19, 2024
Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine.
Journal: JAAD case reports
Published: May 15, 2023
An emerging generation of endocrine therapies in breast cancer: a clinical perspective.
Journal: NPJ breast cancer
Published: September 28, 2022
Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test.
Journal: Breast cancer research and treatment
Published: June 07, 2019
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 18, 2018
Last Updated: 09/26/2026